Peter Devine

Board Member

Peter Devine is CEO of Uniseed and has extensive experience at board and executive management in the commercialisation of early-stage technologies, having held senior R&D, business development and commercialisation positions in Australian companies and Australian universities. He has served on the Board of numerous start-ups that have collectively raised over AU$300 million, with a number of these having done deals collectively worth over AU$2 Billion. Successes include Fibrotech Therapeutics'​ sale to Shire; Spinifex Pharmaceuticals sale to Novartis; Hatchtech's license deal with Dr Reddy's and Kinoxis' collaboration and license deal with Boehringer Ingelheim.

Before joining Uniseed, Peter worked at 4 Australian biotechnology companies including Vice President of Business Development at Progen Industries Ltd and Research, Development and Commercialisation Manager at Brisbane-based PanBio Pty Ltd. He also worked in tech transfer at UniQuest. Prior to this, Peter had a career in academic research, being the recipient of a number of competitive grants, which resulted in numerous patents, publications and scientific presentations at conferences.

Peter holds a PhD from the University of Queensland and received the Dean's Prize and the AGSM Alumni Scholarship for his MBA Studies at the Australian Graduate School of Management. He received a Centenary Medal in 2001 for outstanding contribution to the business of biotechnology, and in 2018 was named in the GUV Powerlist as one of the top 5 people worldwide changing the face of university venturing. He is a Graduate and Fellow of the Australian Institute of Company Directors and holds a Diploma of Financial Services (Financial Markets) and a Graduate Diploma in Applied Finance from Kaplan Professional. In 2011 & 2012, Peter was named on the Kaplan High Achievers Honour Roll.